Mayne Pharma (USA), Inc.
Mayne Pharma (USA), Inc., a prominent player in the pharmaceutical industry, is headquartered in the United States, with significant operations across various regions. Founded in 2013, the company has rapidly established itself as a leader in the development and manufacturing of specialty pharmaceuticals, particularly in the areas of oncology, dermatology, and women's health. Mayne Pharma is renowned for its innovative drug delivery systems and high-quality generic medications, which set it apart in a competitive market. The company’s commitment to research and development has led to several key milestones, including the successful launch of unique formulations that address unmet medical needs. With a strong market position and a focus on patient-centric solutions, Mayne Pharma continues to make significant strides in improving health outcomes globally.
DitchCarbon Score
How does Mayne Pharma (USA), Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Mayne Pharma (USA), Inc.'s score of 13 is higher than 59% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Mayne Pharma (USA), Inc.'s reported carbon emissions
Mayne Pharma (USA), Inc. currently does not have publicly available carbon emissions data or specific reduction targets. As a result, there are no reported figures for their Scope 1, 2, or 3 emissions. The company has not outlined any formal climate commitments or initiatives aimed at reducing carbon emissions. In the context of the pharmaceutical industry, many companies are increasingly focusing on sustainability and climate action, but specific details regarding Mayne Pharma's efforts remain unspecified.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Mayne Pharma (USA), Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
